Comparative Pharmacology
Head-to-head clinical analysis: FLUOROURACIL versus XATMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROURACIL versus XATMEP.
FLUOROURACIL vs XATMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is metabolized to active nucleotides (FdUMP, FUTP) which incorporate into RNA and inhibit thymidylate synthase, leading to cell cycle arrest and apoptosis.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and thereby inhibiting DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through inhibition of purine metabolism and adenosine accumulation.
425 mg/m² IV bolus on days 1-5 every 28 days (Mayo regimen) or 400 mg/m² IV bolus on day 1, then 2400 mg/m² continuous IV infusion over 46 hours (FOLFOX regimen). For topical use, 5% cream applied twice daily for 2-4 weeks.
Methotrexate 10 mg orally once weekly; maximum 25 mg per week.
None Documented
None Documented
Clinical Note
moderateFluorouracil + Digoxin
"Fluorouracil may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFluorouracil + Digitoxin
"Fluorouracil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFluorouracil + Deslanoside
"Fluorouracil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFluorouracil + Acetyldigitoxin
"Fluorouracil may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial α-phase 10-20 min; terminal β-phase 16-20 min (no accumulation). For continuous infusion, functional half-life ~20 min. Clinically, rapid clearance necessitates infusion schedules.
The terminal elimination half-life of methotrexate is approximately 3-10 hours for low doses (<50 mg/m²) and 8-15 hours for high doses (≥500 mg/m²). Prolonged half-life (>24 hours) is associated with renal impairment and drug accumulation, increasing toxicity risk.
Renal: 60-80% as intact drug and metabolites (primarily urea, CO2, α-fluoro-β-alanine). Fecal: <10%. Biliary: minor.
Methotrexate is primarily eliminated renally via glomerular filtration and active tubular secretion. Approximately 80-90% of the dose is excreted unchanged in urine within 24 hours. Fecal excretion is minimal (<10%), with biliary elimination accounting for a small fraction.
Category D/X
Category C
Antimetabolite
Antimetabolite